Michael S. Seaman

发表

Exploiting glycan topography for computational design of Env glycoprotein antigenicity

Douglas A. Lauffenburger, Michael Tiemeyer, Wen-Han Yu, 2018, PLoS Comput. Biol..

Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies

Ming Li, Feng Gao, Amit Kumar, 2010, PLoS Comput. Biol..

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

Maxim N. Artyomov, Michael S. Seaman, Herman N. Eisen, 2010, Nature.

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

Baoshan Zhang, Peter D. Kwong, Michael S. Seaman, 2015, Nature.

Structural basis for membrane anchoring of HIV-1 envelope spike

Michael S. Seaman, Zhijun Liu, James J. Chou, 2016, Science.

Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1

Robin A. Weiss, Paul Kellam, Michael S. Seaman, 2014, PLoS pathogens.

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Ron Diskin, Beatrix Ueberheide, Michael S. Seaman, 2011, Science.

Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

Raphael Gottardo, Hongmei Gao, Bette T. Korber, 2013, Journal of Virology.

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Michael S. Seaman, Florian Klein, Anthony P. West, 2015, Nature.

Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth

Bette Korber, Gwo-Yu Chuang, Peter D. Kwong, 2018, Cell reports.

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

Tongqing Zhou, Ron Diskin, Peter D. Kwong, 2013, Cell.

Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C

Lynn Morris, Michael S. Seaman, John R. Mascola, 2008, Journal of Virology.

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

Michael S. Seaman, Yan Liu, Pamela J. Bjorkman, 2012, Proceedings of the National Academy of Sciences.

Computational Prediction of Broadly Neutralizing HIV-1 Antibody Epitopes from Neutralization Activity Data

Andrew L. Ferguson, Michael S. Seaman, Arup K. Chakraborty, 2013, PloS one.

Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design

Ron Diskin, Michael S. Seaman, Florian Klein, 2011, Science.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

James Theiler, Karina Yusim, S. Gnanakaran, 2019, Cell host & microbe.

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Mario Roederer, Tongqing Zhou, Gary J. Nabel, 2010, Science.

Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

Jian Yu, Michael S. Seaman, D. Ho, 2016, Cell.

HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes

Michael S. Seaman, John R. Mascola, Martha Nason, 2012, Journal of Virology.

Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys

Bette Korber, Michael S. Seaman, James J. Szinger, 2010, Nature Medicine.

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

Lynn Morris, Bette Korber, Tanmoy Bhattacharya, 2016, PLoS pathogens.

A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection

Yoshiaki Nishimura, Michael S. Seaman, Dean A. Follmann, 2018, Nature Medicine.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Nico Pfeifer, Michael S. Seaman, Florian Klein, 2018, Nature.

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein

Lynn Morris, Yan Liu, Michael S. Seaman, 2012, The Journal of experimental medicine.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

Richard T. Wyatt, Michael S. Seaman, John R. Mascola, 2009, Nature.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

Ron Diskin, Michael S. Seaman, Florian Klein, 2012, Nature.

Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV

William R. Schief, Michael S. Seaman, Dennis R. Burton, 2014, Science Translational Medicine.

The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies

Daphne Koller, George M. Church, Jonathan Laserson, 2013, PLoS pathogens.

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

Nico Pfeifer, Michael S. Seaman, Florian Klein, 2016, Science.

Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys

Michael S. Seaman, Florian Klein, Arup K. Chakraborty, 2013, Nature.

PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4

Tongqing Zhou, Terri Wrin, Peter D. Kwong, 2012, Journal of Virology.

Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

Ron Diskin, Michael S. Seaman, Florian Klein, 2013, The Journal of experimental medicine.

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Nico Pfeifer, Michael S. Seaman, Florian Klein, 2016, Nature.